Proteasome inhibitor bortezomib is an effective therapy for relapsed and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance can limit its long-term utility. Recent research has focused on targeting ubiquitin receptors upstream of 20S proteasome, with the aim of generating less toxic therapies. Here we show that 19S proteasome-associated ubiquitin receptor Rpn13 is more highly expressed in MM cells than in normal plasma cells. Rpn13-siRNA (small interfering RNA) decreases MM cell viability. A novel agent RA190 targets Rpn13 and inhibits proteasome function, without blocking the proteasome activity or the 19S deubiquitylating activity. CRISPR/Cas9 Rpn13-knockout demonstrates that RA190-induced activity is dependent on Rpn13. RA190 decreases viability in MM cell lines and patient MM cells, inhibits proliferation of MM cells even in the presence of bone marrow stroma and overcomes bortezomib resistance. Anti-MM activity of RA190 is associated with induction of caspase-dependent apoptosis and unfolded protein response-related apoptosis. MM xenograft model studies show that RA190 is well tolerated, inhibits tumor growth and prolongs survival. Combining RA190 with bortezomib, lenalidomide or pomalidomide induces synergistic anti-MM activity. Our preclinical data validates targeting Rpn13 to overcome bortezomib resistance, and provides the framework for clinical evaluation of Rpn13 inhibitors, alone or in combination, to improve patient outcome in MM.
INTRODUCTION
Normal cellular homeostasis is maintained by a balanced regulation of protein synthesis and degradation. The ubiquitin (Ub) proteasome system (UPS) is a non-lysosomal intracellular protein degradation pathway mediated via proteasome holoenzymes, Ub ligases and deubiquitylating enzymes (DUBs). [1] [2] [3] [4] [5] Proteasomal protein degradation occurs through these sequential events: protein is first marked with a chain of small polypeptides called Ub; E1 Ub enzyme then activates Ub and links it to the Ub-conjugating enzyme E2 in an ATP-dependent manner; E3 Ub ligase then links the Ub molecule to the protein; a long polypeptide chain of Ub moieties is formed; and finally, proteasomes degrade protein into small fragments and free Ub for recycling. 3, 6 Recent studies have delineated the mechanism(s) whereby 26S proteasome recognizes its substrates. 7, 8 Specifically, Ub-tagged proteins are recognized by 19S proteasome-associated Ub receptors Rpn13 and Rpn10; the Ub moiety is then removed from the substrate protein via DUB enzymatic activity; the target protein is then unfolded by the AAA-ATPases, followed by degradation of proteins through 20S proteolytic activities. 5, [9] [10] [11] The Ub proteasome pathway is a validated therapeutic target in multiple myeloma (MM), evidenced by the US Food and Drug Administration approval of bortezomib, carfilzomib and ixazomib. [12] [13] [14] [15] [16] Although bortezomib, carfilzomib and ixazomib therapies are major advances, they are associated with possible off-target toxicities and the eventual development of drug resistance. [17] [18] [19] [20] [21] [22] [23] Therapeutic strategies directed against DUBs or Ub receptors upstream of the 20S proteasome may allow for more specific targeting of the UPS, with fewer off-target activities and toxicities. Our recent study exemplifies the feasibility of such an approach: specifically, we showed that blockade of 19S-associated DUBs USP14/UCHL5 with a small-molecule inhibitor (bAP15/VLX1570) induces apoptosis in MM cells and overcome bortezomib resistance, with a favorable toxicity profile. 24 These preclinical findings provided the basis for an ongoing first-in-human clinical trial of USP14/UCHL5 DUB inhibitor bAP15/VLX1570 to treat relapsed or relapsed and refractory MM.
Besides DUB inhibitors, a recent study highlighted the therapeutic potential of targeting Ub receptor Rpn13 to inhibit proteasome function. 25, 26 The rationale for targeting Rpn13 (also known as adhesion-regulating molecule-1) is based on earlier reports 7, 8, 27, 28 showing that Rpn13 links two essential steps for protein degradation: Rpn13 both recognizes the ubiquitylated proteins and facilitates their disassembly by interacting with DUB enzymes USH37/Rpn11 at the 19S proteasome, allowing for protein degradation via the 20S proteasome. Furthermore, Rpn13 is associated with immune response signaling.
Here we used MM cell lines and primary patient cells, as well as an in vivo human MM xenograft model, to examine the functional and biological significance of Rpn13 in MM cells. Our studies show that genetic or pharmacological blockade of Rpn13 triggers MM cytotoxicity, overcomes proteasome inhibitor resistance and induces anti-MM immunity, providing the rationale for novel therapeutics targeting Rpn13 to improve patient outcome in MM. 
MATERIALS AND METHODS

Immunoblotting
Total cell lysates were subjected to immunoblotting using antibodies against poly-ADP ribose polymerase (PARP; BD Bioscience Pharmingen, San Diego, CA, USA), caspase-3, caspase-8, p53 (Santa Cruz Biotechnology, Inc.), caspase-9, p-eIF2α (Abcam, Cambridge, MA, USA), caspase-7, cyclin B1, CDC25C, CDC2, p21, Rpn13, PERK, BIP, Calnexin, GAPDH, GFP, LC3A/B (Cell Signaling, Beverly, MA, USA), poly-Ub (Enzo Life Sciences), UCH37
(Gene Tex Inc., Irvine, CA, USA), Ub (EMD Millipore, Billerica, MA, USA) or β-actin (Sigma-Aldrich, St Louis, MO, USA).
Ub-vinyl sulfone probe labeling and proteasome activity assays MM.1S cells were treated with RA190 (300 nM) or bAP15 (100 nM) for 3 h; cells were then harvested and lysed in lysis buffer, followed by removal of debris by centrifugation. 24 Total protein (25 μg) was labeled with 1 μM hemagglutinin (HA)-tagged Ub-vinyl sulfone probe for 30 min at 37°C, and then subjected to western blotting. 30 Proteasome activity was measured using 20S Proteasome Assay Kit (Calbiochem, San Diego, CA, USA), as described previously. 31 Cell viability and apoptosis analysis Cell viability was assessed by WST-1 (Clontech Laboratories, Inc., Mountain View, CA, USA)/CellTiter-Glo Luminescent (Promega Corporation, Madison, WI, USA) assays, as described previously. 32 Apoptosis was measured using Annexin/PI staining. 33 Caspase activity and cell-cycle analysis was performed as described previously. 34 Human plasmacytoma xenograft models
All animal experiments were approved by and conformed to the relevant regulatory standards of the Institutional Animal Care and Use Committee at the Dana-Farber Cancer Institute (Boston, MA, USA). The human plasmacytoma xenograft model was performed as described previously. 29 Analysis of tumors harvested from mice using immunostaining and immunoblotting
Sections of tumors harvested from mice were subjected to immunostaining for detection of growth inhibition (Ki67), apoptosis (caspase-3), polyubiquitination (PolyU) and angiogenesis (CD31), as described previously. 29, 32 Tumor lysates from control vehicle-and RA190-treated mice were subjected to immunoblot analyses using antibodies against PARP, caspase-7, poly-Ub or β-actin.
Statistical analysis
Statistical significance was determined using the Student's t-test. Survival of mice was determined by GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA). Isobologram analysis was performed using the CalcuSyn software program (Biosoft, Cambridge, UK).
RESULTS
Expression and functional significance of Rpn13 in MM cells
Gene expression analysis using reverse transcription-PCR showed that Rpn13 is highly expressed in patient MM cells vs normal PBMCs (Figure 1a ; forward primer: 5′-GACTCCGGATAAGCGGAAAG-3′ and reverse primer: 5′-ATGTTTCCCAGCAGGCTCT-3′). Consistent with these findings, higher Rpn13 protein expression was observed in both MM cell lines and patient tumor cells vs normal PBMCs (Figure 1b) . Immunohistochemistry studies using BM biopsies from MM patients and normal healthy donors showed elevated Rpn13 expression in MM cells vs normal cells (Figure 1c) .
We next examined whether Rpn13 is functionally significant in MM. For these studies, we performed loss-of-function studies using small interfering RNA (siRNA) against Rpn13. The specificity of Rpn13-siRNA was confirmed by a marked decrease in the expression of Rpn13 (Figure 1d, immunoblot) . Transfection of MM cells with Rpn13-siRNA, but not scr-siRNA, triggered a significant decrease in their viability ( Figure 1d , bar graph; Po0.0001). These data suggest a role for Rpn13 in the survival of MM cells, and provide the rationale for potential therapeutic targeting of Rpn13 in MM cells.
Biochemical characterization of a novel inhibitor of Rpn13 RA190 Recent research efforts 25 led to the discovery and development of a novel amino-acid chalcone conjugate RA190 that targets Rpn13 (Figure 2a ). Direct binding of RA190 to Rpn13 prevents recognition of polyubiquitylated proteins at the 19S proteasome, which is an essential early event required for deubiquitylation and degradation of proteins via the 20S proteasome. 25 To further determine the specificity of RA190 against Rpn13, we performed CRISPR/Cas9 genome editing to generate Rpn13-KO HCT116 cell lines, and then examined the effect of RA190 treatment on these cells. Treatment of Rpn13-wild-type (WT) HCT116 cells with RA190 triggered a dose-dependent decrease in the viability of these cells; conversely, a marked reduction in RA190 cytotoxic activity was observed against HCT116-Rpn13-KO cells (Figure 2b ). Transient transfection of Rpn13-WT in HCT116-Rpn13-KO cells restored the sensitivity to RA190 (Figure 2c ). RA190 binds to the cysteine 88 in the Pru domain of Rpn13; and importantly, transient transfection of cysteine 88-mutated Rpn13 (Rpn13-MT) in the HCT116-Rpn13-KO did not restore response to RA190 treatment ( Figure 2c ). As for Rpn13-siRNA-transfected MM.1S cells (Figure 1d ), KO of Rpn13 in these cells decreased their survival time (3-5 days), which suggests different roles of Rpn13 in MM.1S and HCT116 cell lines. These findings demonstrate that RA190-induced activity is predominantly dependent on Rpn13.
We next examined the effect of RA190 on proteasome function and DUB activity in MM cells. It is well established that inhibition of the proteasome causes accumulation of ubiquitinated proteins. 35 A comparative analysis showed that RA190 induced a more rapid accumulation of distinctly higher-molecular-weight polyubiquitylated proteins than bortezomib in MM.1S cells (Figure 2d , left panel). These data indicate distinct mechanisms of action of RA190 vs bortezomib. Indeed, bortezomib, unlike RA190, does not inhibit deubiquitylation of proteins at the 19S proteasome, and therefore generates lower-molecular-weight polyubiquitylated proteins. Of note, a similar accumulation of polyubiquitylated proteins was noted in bortezomib-resistant ANBL6.BR cells in response to RA190 treatment (Figure 2d, right panel) .
To determine whether RA190 blocks cellular proteasome function, we used a reporter cell line expressing Ub-tagged GFPu-1 that is constitutively targeted for proteasomal degradation. A dose-dependent accumulation of Ub-GFP was noted in response to the treatment of GFPu-1 cells with RA190, indicating impaired proteasome degradation (Figure 2e ). On the other hand, treatment of MM.1S cells with RA190 (1-10 μM) for 3 h did not affect chymotrypsin-, trypsin-or caspase-like proteasome activities ( Figure 2f) ; bortezomib served as a control for inhibition of chymotrypsin-like activity.
Rpn13 engages 19S-associated DUB during protein degradation. In mammalian cells, three DUBs are associated with the proteasome: USP14, UCH37 and Rpn11. 28, [36] [37] [38] Both USP14 and UCH37 reversibly associate with the 19S regulatory particle, whereas Rpn11 is an intrinsic subunit of the proteasome lid subcomplex of the 19S regulatory particle. Our recent study showed that DUB inhibition results in accumulation of polyubiquitylated proteins; 24, 32 and importantly, similar results were noted upon treatment of MM cells with Rpn13 targeting agent RA190 (Figure 2e ). Indeed, RA190 targets Rpn13; however, based on our findings RA190-induced polyubiquitylation might also be due to off-target inhibitory activity of RA190 against 19S-associated DUB activity, and whether RA190 affects cellular DUB activity in MM cells is unknown. To address this issue, we first tested cellular DUB activity using the substrate Ub-7-amino-4-methycoumarin (Figure 3a ) on RA190-treated cells. We observed no reduction in total cellular DUB enzymatic activity; Ub aldehyde (Ubal) served as a positive control for DUB inhibition (Figure 3b ). In vitro assays using purified 19S proteasome-associated DUBs confirmed no significant inhibitory activity of RA190 against USP14, UCH37/UCHL5 or Rpn11 (Figure 3c ).
To further determine whether RA190 affects DUB activity, we performed competition assays between RA190 and Ub active site probe Ub-VS (HA-Ub-VS). 39 MM.1S cells were treated with RA190, bAP15 (UCH37 inhibitor) or Ubal; protein lysates were incubated with Ub-VS probe for 30 min, followed by immunoblot analysis with anti-UCH37 antibody. Untreated cell lysates incubated with Ub-VS probe exhibited Ub-VS-UCH37 conjugate formation, as reflected by the increase in mass of UCH37 of~10 kDa; and importantly, a similar degree of Ub-VS-labeling was noted in RA190-treated cells (Figure 3d ). In contrast and as in our prior study, 24 Ub-VS-UCH37 conjugate formation was inhibited in cell lysates from bAP15-or Ubal-treated cells (Figure 3d ). These data suggest that RA190 does not block UCH37 DUB activity in cellular microenvironment. Additional evidence for the lack of RA190 activity against DUBs was obtained from K48-linked Ub-tetramer chain cleavage assays in the presence of purified 19S, which show that RA190 does not inhibit Ub chain disassembly (Figure 3e ). Taken together, these findings suggest that targeting Ub receptor Rpn13 with RA190 blocks proteasome function without inhibiting either 19S-associated DUBs or 20S proteolytic activities. This strategy may therefore overcome bortezomib resistance due to mutations or defects in 20S core proteolytic activities. Our recent studies have identified an integral role of pDCs in MM pathogenesis. 29, 41, 42 Specifically, we showed that pDCs are relatively resistant to novel and conventional therapies; protect tumor cells from therapy-induced cytotoxicity; promote tumor growth and survival; as well as suppress immune responses. 29, 41, 42 We therefore next examined the effect of RA190 on pDC-induced MM cell growth. MM.1S cells and patient pDCs were cultured either alone or together. Cells were treated with RA190 for 48 h, and growth was measured using 5-bromo-2′-deoxyuridine proliferation assay. A significant inhibition of pDC-induced MM.1S cell growth was observed in response to treatment with RA190 ( Figure 4f ). RA190 did not affect the viability of pDCs (data not shown).
Mechanism(s) mediating the anti-MM activity of RA190
To delineate the mechanism of action underlying RA190-induced MM cell death, MM.1S cells were treated with RA190 (300 nM) for 24 h, and then subjected to both cell-cycle and apoptosis analysis. RA190 induced significant G2/M-phase growth arrest, with a concomitant increase in the S phase (Figure 5a ). Consistent with these findings, RA190 treatment decreased G2/M-phase cellcycle regulatory protein CDC25C and its downstream protein CDC2, as well as cyclin B1 in MM.1S (Figure 5b, left panel) . A similar observation was noted in bortezomib-resistant ANBL6.BR MM cells in response to treatment with RA190 (Figure 5b, right panel) . We next examined whether anti-MM activity of RA190 is due to apoptosis. RA190 induced a significant increase in both early and late apoptotic cell populations, assessed by Annexin V/PI staining ( Figure 5c ). Furthermore, treatment of MM.1S or ANBL6.BR cells with RA190 triggered a marked increase in PARP cleavage, a signature event during apoptosis (Figure 5d ). Similarly, RA190 induced cleavage of caspase-3 (Figure 5d ), an upstream activator of PARP as well as caspape-7. Furthermore, we found that RA190 induces activation of both caspase-8-and casapse-9-mediated apoptotic signaling cascades (Figures 5d  and 6a) . Importantly, blockade of caspases using a pancaspase inhibitor significantly decreased RA190-induced MM cell death (Figure 6b ). In addition, specific inhibitors of caspase-3, caspase-8 or caspase-9 also blocked RA190-triggered MM cell death (data not shown). Similar effects on cell-cycle, apoptosis and activation of caspases were shown in Rpn13-siRNA knockdown MM.1S cells (data not shown).
RA190 triggers ER stress response, p53/p21 signaling axis and autophagy in MM cells Accumulation of ubiquitylated (misfolded/unfolded) proteins triggers the unfolded protein response and apoptosis. 35 Our comparative analysis showed that RA190 triggers an earlier and more robust accumulation of polyubiquitylated proteins than bortezomib. We therefore next examined whether RA190 vs bortezomib induce endoplasmic reticulum (ER) stress response signaling with a similar kinetics. For these studies, we performed a head-to-head experiment comparing the effect of RA190 and bortezomib: MM.1S cells were treated with IC 50 doses of RA190 or bortezomib for various time periods; and protein lysates were then analyzed for ER signaling proteins p-eIF2α, PERK, BIP or calnexin. RA190 triggered a significant upregulation of p-eIF2α, PERK or BIP as early as 4 h (Figure 6c, left panel) . Similar results were observed for p-eIF2α and BIP after longer time periods (16 h) of bortezomib treatment, whereas bortezomib only modestly induced PERK (Figure 6c, left panel) . As for p-eIF2α, PERK, BIP or calnexin, RA190 also triggered an early induction of p53 and p21 compared with bortezomib-treated MM cells (Figure 6c, left  panel) . This rapid induction kinetics of ER stress response signaling correlated with early and robust accumulation of polyubiquitylated proteins in RA190-vs bortezomib-treated cells. Of note, we found that RA190, but not bortezomib, induced ER protein calnexin (Figure 6c, left panel) . Similar to our observation in MM.1S cells, RA190 triggered ER stress response signaling in bortezomibresistant ANBL6.BR cells, evidenced by induction of p-eIF2α, PERK, BIP, p53 and p21 (Figure 6c, right panel) .
Besides induction of ER stress and apoptosis, proteasome inhibition is associated with induction of autophagy. Consistent with these findings, treatment of MM.1S and ANBL6.BR cells with RA190 induced cleavage of autophagy-associated protein LC3A/B (Figure 6c ). Earlier reports linked bortezomib resistance to the induction of autophagy; this notion led to an ongoing clinical trial of combined bortezomib and an autophagy inhibitor hydroxychloroquine in MM patients. 43 Whether RA190-induced autophagy results in the development of drug resistance remains to be determined, but our findings indicate the therapeutic potential of combining inhibitors of Rpn13 and autophagy. .BR and MM.1S cells were treated with DMSO or RA190 for 12 h; protein lysates were then subjected to immunoblotting using antibodies specific for cyclin B1, CDC2, CDC25C or GAPDH. (c) MM.1S cells were treated with DMSO or RA190 (300 nM) for 24 h, and then analyzed for apoptosis with Annexin V/PI double staining assay (mean ± s.d.; n = 3; P o0.001). (d) ANBL6.BR and MM.1S cells were treated with DMSO or RA190 for 12 h; protein lysates were then subjected to immunoblotting using antibodies against caspase-3, caspase-7, caspase-8, caspase-9, PARP or β-actin.
RA190 inhibits human MM cell growth in vivo and prolongs survival in a xenograft mouse model We next examined the in vivo efficacy of RA190 treatment by using human plasmacytoma MM.1S xenograft mouse models. 29, [31] [32] [33] This model has been useful in extensively validating novel anti-MM therapies bortezomib, lenalidomide or pomalidomide, leading to their translation to clinical trials and FDA approval for the treatment of MM. Treatment of MM.1S tumor-bearing mice with intraperitoneal injection of RA190 (15 mg/kg) inhibits MM tumor growth and prolongs survival of these mice (Figures 7a and b) . RA190 treatment was well tolerated, as no significant weight loss was observed. We next examined the tumors from control vehicleor RA190-treated mice to determine the in vivo activity profile of RA190. Immunoblotting of lysates from harvested tumors revealed a marked increase in PARP cleavage, caspase-7 activation and polyubiquitylation in tumor lysates from RA190-vs control vehicletreated mice (Figure 7c ). As seen in Figure 7d , immunostaining of tumors from RA190-treated mice vs control mice showed that RA190 (1) increases the number of cleaved caspase-3-positive apoptotic tumor cells; (2) decreases proliferation in tumors, as assessed by Ki67 staining; (3) reduces angiogenesis, as evidenced by decreased staining for angiogenesis-related CD31; and (4) increases polyubiquitylation. Taken together, these data show potent in vivo apoptotic activity of RA190 against MM cells.
Combining RA190 with lenalidomide, pomalidomide or bortezomib triggers synergistic anti-MM activity Preclinical and clinical studies show that combining anti-MM agents enhances cytotoxicity, reduces toxicity and overcomes drug resistance. We therefore next examined whether blockade of Rpn13 with RA190 adds to the anti-MM activity of other drugs. MM.1S cells were treated with RA190 and lenalidomide, pomalidomide or bortezomib across a range of concentrations for 48 h, and then analyzed for viability. Isobologram analysis for synergistic anti-MM activity demonstrated that the combination of low concentrations of RA190 and lenalidomide, pomalidomide or bortezomib triggered synergistic anti-MM activity, with a confidence interval o 1.0 (Figures 8a-c) .
DISCUSSION
Our studies use MM cell lines, patient tumor cells and MM xenograft models, as well as biochemical and genetic models, to validate Ub receptor Rpn13 as a promising therapeutic target in MM. Reverse transcription-PCR and western blot analyses show that Rpn13 is highly expressed in MM cell lines and patient tumor cells vs normal cells. Immunohistochemistry studies of BM biopsies from MM patients and normal healthy donors showed significantly higher Rpn13 expression in MM cells than in normal cells. A similarly high Rpn13 expression has been reported in ovarian and colon cancer. [44] [45] [46] [47] These data suggest a role of Rpn13 in the pathogenesis of MM.
The functional significance of Rpn13 in MM cells was examined using both RNA interference and biochemical strategies. Blockade of Rpn13 using siRNA decreases viability of MM cells. These data are in concert with earlier reports that Rpn13 KD inhibits proliferation and induces apoptosis in hepatocarcinogenesis models. 48 We next used a novel agent RA190 that targets Rpn13. 25 The specificity of Rpn13 inhibitor RA190 was confirmed using multiple strategies: first, assays using CRISPR/Cas9 Rpn13-KO cells shows that loss of Rpn13 triggers cell death; conversely, rescue experiments with Rpn13-WT in Rpn13-KO cells restores sensitivity to RA190; second, RA190 impaired cellular protein degradation, assessed using a reporter cell line expressing Ub-tagged GFPu-1 and polyubiquitylation; third, RA190 blocks proteasome function without inhibiting the 20S proteasomal activities; and fourth, studies using both cellular extracts and recombinant proteins to assess DUB activity show that RA190 does not inhibit 19S-associated DUB activity. Taken together, our data indicate that targeting Rpn13 with RA190 inhibits proteasome function without blocking either 19S-associated DUBs or 20S proteolytic activities. These finding highlight the therapeutic potential of RA190 to overcome bortezomib resistance due to mutations or defects in 20S core proteolytic activities. Analysis of RA190 efficacy in in vitro model of MM shows that RA190 inhibits growth and induces apoptosis in tumor cells, without affecting the viability of normal PBMCs. The anti-MM activity of RA190 was observed against MM cell lines, including those sensitive and resistant to conventional and novel therapies, as well as representing distinct cytogenetic profiles. 49, 50 For example, we studied: isogenic cell lines Dex-sensitive MM.1S and Dex-resistant MM.1R with t(14;16) translocation and c-maf overexpression; RPMI-8226 parental cell line and its drug-resistant derivatives (Dox40 or LR5) with TP53, K-Ras and EGFR mutations; or interleukin-6-dependent cell lines INA6 and ANBL6 with N-Rasactivating mutations. [49] [50] [51] [52] [53] The variable IC 50 of RA190 against these MM cell lines may be due to their distinct genetic backgrounds and/or drug resistance characteristics. We further show that RA190 triggers apoptosis in MM cells, even in the presence of the MMhost BM microenvironment. These data suggest that RA190 not only targets MM cells directly but also overcomes the cytoprotective effects of the MM-host BM microenvironment. Mechanistic studies show that RA190-triggered apoptosis in MM.1S cells is associated with activation of caspase-3, caspase-7, caspase-8, caspase-9 and PARP cleavage. These findings suggest that RA190 triggers both mitochondria-dependent and -independent signaling pathways and that apoptosis is mediated via caspases. Moreover, RA190 induces p53 and p21, as well as ER stress response signaling molecules (p-eIf2α, PERK, BIP, calnexin) and autophagy. A similar induction profile of caspases, ER stress response signaling and autophagy was noted in RA190-treated ANBL6.BR cells. Taken together, our data demonstrate that anti-MM activity of RA190 is associated with a rapid and robust induction of ER stress response, activation of caspase cascade, p53/p21 signaling axis and autophagy.
In animal tumor model studies, RA190 is well tolerated, inhibits tumor growth in vivo and prolongs host survival. Immunostaining of harvested tumors confirms the in vitro mechanisms of action and further show that antiangiogenic activity contributes to the overall antitumor activity of RA190. Finally, combining RA190 with lenalidomide, pomalidomide or bortezomib induces synergistic anti-MM activity. We found that the combination of lower concentrations of RA190 and pomalidomide triggered greater anti-MM activity compared with RA190 plus bortezomib or lenalidomide. This is likely due to the induction of distinct and/or broader apoptotic mechanism of action of RA190 with pomalidomide than with either bortezomib or lenalidomide. Future clinical trials will assess whether combination strategies blocking Rpn13 with anti-MM agents reduces toxicity. Moreover, the synergy observed in vitro indicates the potential for use of lower doses and decreased attendant toxicity.
Our preclinical studies therefore provide the rationale for the development of next-generation UPS-based therapies, and specifically demonstrate the promise of therapeutics targeting Ub receptor Rpn13, alone or in combination, to improve patient outcome in MM. 
